DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.
Also called NCT02110303
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 220 participants
- Registry
-
NCT02110303
-
- Other papers using this trial's data
- Coronary 18F-Fluoride Uptake and Progression of Coronary Artery Calcification
- Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02110303. Randomized; quadruple masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2017-05-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
- Acronym
- DIAMOND
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Ticagrelor
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Edinburgh
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02110303- Content hash
a2687fe9421d9129fdc360e2b747f68e4e898bc83a34037fd397daf5cf6ac28d